期刊文献+

洛伐他汀自组装前体脂质体的制备及其理化性质的研究

Preparation and Characterization of Lovastatin Self-assemble Proliposomes
下载PDF
导出
摘要 目的:为研究洛伐他汀新剂型,制备洛伐他汀新型前体脂质体,并对其质量进行考察。方法:采用一种新型前体脂质体制备方法将洛伐他汀制成自组装前体脂质体,对水合后脂质体的形态、粒径、Zeta电位、包封率、自组装速度、稳定性等进行考察,验证这种新型前体脂质体制备方法用于制备洛伐他汀脂质体的可行性。结果:所形成的洛伐他汀脂质体包封率为95.4%±6.7%,平均粒径为(327.4±29.6)nm,Zeta电位值为-(22.4±1.5)mV。洛伐他汀自组装前体脂质体可在60 s内自发形成脂质体并达到分散平衡;以人工胃液为稀释介质,洛伐他汀脂质体在12 h内稳定。结论:采用新型前体脂质体制备方法可将洛伐他汀制成洛伐他汀脂质体,形成的脂质体包封率较高且具有良好的稳定性。 To investigate the possibility of liquid proliposomes being carriers for oral delivery,lovastatin self-assemble proliposomes were prepared.Lovastatin proliposomes were characterized by conversion rate from proliposomes to liposomes,entrapment efficiency(EE,%),particle size and shape,zeta potential and stability.Results showed that lovastatin proliposomes were automatically converted into liposomes when exposed to a water phase in 60 s.The average diameter was 327.4±29.6 nm in distilled water with entrapment efficiency of 95.4±6.7%,zeta potential of-(22.4±1.5) mV.The stability study showed that entrapment efficiency and particle size of lovastatin liposomes remained unchanged for 12 h.
出处 《药学与临床研究》 2012年第3期181-184,共4页 Pharmaceutical and Clinical Research
关键词 洛伐他汀 前体脂质体 包封率 Lovastatin Proliposomes Entrapment efficiency
  • 相关文献

参考文献5

二级参考文献46

  • 1杨志军,日野知证,川岛嘉明.黄芩前体脂质体再复水后的新脂质体粒径研究[J].中国药科大学学报,1993,24(3):161-164. 被引量:12
  • 2王会娟,李馨儒,黄燕清,张云龙,胡新,刘艳.番茄红素微囊的体内外药剂学行为[J].药学学报,2005,40(9):787-791. 被引量:13
  • 3高坤,孙进,何仲贵.肠道转运蛋白在药物吸收中的重要作用[J].药学学报,2006,41(2):97-102. 被引量:17
  • 4马广立,程翼宇.口服药物生物利用度预测研究进展[J].药学学报,2006,41(10):917-920. 被引量:4
  • 5Itoh K,Tozuka Y, Oguchi T, et al. Improvement of physicochemical properties of N-4472 part Ⅰ formula design by using self-microemulsifying system [ J ]. Int J Pharm, 2002,238 ( 1-2 ) : 153 - 160.
  • 6Ashington C. Drug release from microdisperse systems:a critical review [ J ].Int J Pharm, 1990,58 ( 1 ) : 1 - 12.
  • 7Levy MY, Benita S. Drug release from submicronized O/W emulsion:a new in vitro kinetic evaluation model [ J ]. Int J Pharm, 1990,66(1-3) :29 -37.
  • 8邱洪 祁哲 陈纪林 等.普伐他汀导致横纹肌溶解症一例[J].中国循环杂志,1998,13:374-379.
  • 9Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279:1615-1622.
  • 10Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med, 1998, 158:577-584.

共引文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部